_
Alzheimer's cure: World General Media News Headlines
Alzheimer's treatment: World General Media News Headlines
Alzheimer theories: World General Media News Headlines
Alzheimer science professional news: Alzforum News & Views
August 06, 2005
ISOA and Elan Pharmaceuticals Co-Fund New Grant Program
"Ireland-based Elan Pharmaceuticals, Inc. (Elan), whose expertise in the neuroscience field is highly respected [AC: Make sure you read footnote below], has teamed up with the Institute for the Study of Aging (ISOA) in New York City to establish new grants to catalyze and accelerate the global discovery and development of new drugs for Alzheimer’s disease. The objective of this Request for Proposal (RFP) program is to support the development of lead compounds through preclinical in-vitro and in-vivo evaluation, including pharmacology, toxicology, pharmacokinetics, formulation chemistry and the conduct of pre-clinical “proof of concept” studies. Four 1-yr grants are available for $130K/yr. Applicants must hold an M.D. or Ph.D. degree. Applications and supporting materials must be received by October 14, 2005. See more details on the ISOA web site."
Source: AlzForum web site (last viewed 5 August 2005) [FullText: Link 1 Link 2 Link 3 (Doc file) ]
Footnote: Make Sure You Know that Elan Directors were in preslump shares sales a year before the company publicly announced poor results in its' trial of amyloid-based Alzheimer's disease treatment with a vaccine. See Ireland The Business Post publications for further details: 18 August 2005 and 11 August 2005 . The non-disclosure of competing interest by Elan Director and Harward Professor Dennis Selkoe (and other scientists in Alzheimer's field) could well led to sad storied of Alzheimer's patients families, such as the one described in the article "Good buy came early".
Source: AlzForum web site (last viewed 5 August 2005) [FullText: Link 1 Link 2 Link 3 (Doc file) ]
Footnote: Make Sure You Know that Elan Directors were in preslump shares sales a year before the company publicly announced poor results in its' trial of amyloid-based Alzheimer's disease treatment with a vaccine. See Ireland The Business Post publications for further details: 18 August 2005 and 11 August 2005 . The non-disclosure of competing interest by Elan Director and Harward Professor Dennis Selkoe (and other scientists in Alzheimer's field) could well led to sad storied of Alzheimer's patients families, such as the one described in the article "Good buy came early".
posted by Dr. Koudinov @ 6.8.05
Latest PubMed 20 review articles on Alzheimer’s
Latest PubMed 20 research articles on Alzheimer’s amyloid
Latest PubMed 50 research titles on Alzheimer’s
0 Comments:
Post a Comment
<< Home